Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Gancotamab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Gancotamab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Gancotamab. |
| Estrone | Estrone may increase the thrombogenic activities of Gancotamab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Gancotamab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Gancotamab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Gancotamab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Gancotamab. |
| Estriol | Estriol may increase the thrombogenic activities of Gancotamab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Gancotamab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Gancotamab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Gancotamab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Gancotamab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Gancotamab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Gancotamab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Gancotamab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Gancotamab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Gancotamab. |
| Equol | Equol may increase the thrombogenic activities of Gancotamab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Gancotamab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Gancotamab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Gancotamab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Gancotamab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Gancotamab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Gancotamab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Gancotamab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Gancotamab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Gancotamab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Gancotamab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Gancotamab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Gancotamab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gancotamab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Gancotamab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Gancotamab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Gancotamab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gancotamab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gancotamab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Gancotamab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Gancotamab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Gancotamab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Gancotamab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gancotamab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gancotamab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Gancotamab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gancotamab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gancotamab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Gancotamab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gancotamab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Gancotamab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Gancotamab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Gancotamab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gancotamab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gancotamab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Gancotamab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Gancotamab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Gancotamab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Gancotamab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Gancotamab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Gancotamab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Gancotamab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Gancotamab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Gancotamab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Gancotamab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Gancotamab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Gancotamab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Gancotamab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Gancotamab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Gancotamab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Gancotamab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Gancotamab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Gancotamab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Gancotamab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Gancotamab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Gancotamab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Gancotamab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Gancotamab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Gancotamab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Gancotamab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Gancotamab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Gancotamab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Gancotamab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Gancotamab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Gancotamab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Gancotamab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Gancotamab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Gancotamab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Gancotamab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Gancotamab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Gancotamab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Gancotamab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Gancotamab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Gancotamab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Gancotamab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Gancotamab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Gancotamab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Gancotamab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Gancotamab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Gancotamab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Gancotamab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Canakinumab is combined with Gancotamab. |